Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,195 shares of the company’s stock after selling 565 shares during the quarter. Yousif Capital Management LLC’s holdings in Pacira BioSciences were worth $783,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pacira BioSciences by 96.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock valued at $36,000 after acquiring an additional 583 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 310.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company’s stock valued at $61,000 after acquiring an additional 1,514 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Pacira BioSciences by 63.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,481 shares of the company’s stock valued at $137,000 after acquiring an additional 1,736 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Pacira BioSciences by 9.4% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company’s stock valued at $157,000 after acquiring an additional 438 shares during the last quarter. Finally, Trust Point Inc. purchased a new stake in shares of Pacira BioSciences in the 4th quarter valued at $245,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Activity

In related news, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the sale, the director now directly owns 140,384 shares in the company, valued at $4,165,193.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Gary W. Pace sold 90,000 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the sale, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 9th. JPMorgan Chase & Co. initiated coverage on shares of Pacira BioSciences in a report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Monday, March 4th. Royal Bank of Canada lowered their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, Wedbush reissued an “outperform” rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Thursday, February 8th. Eleven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $49.50.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $27.21 on Monday. The firm has a 50-day simple moving average of $28.41 and a 200-day simple moving average of $29.54. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of 33.59 and a beta of 0.77. The company has a quick ratio of 4.17, a current ratio of 5.24 and a debt-to-equity ratio of 0.59. Pacira BioSciences, Inc. has a 52 week low of $25.33 and a 52 week high of $44.62.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, meeting analysts’ consensus estimates of $0.71. The business had revenue of $181.24 million during the quarter, compared to analysts’ expectations of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. On average, equities analysts predict that Pacira BioSciences, Inc. will post 2.17 earnings per share for the current fiscal year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.